Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-118 in allergic conjunctivitis
NCT01541904Phase 2Withdrawn
- Sponsor
- Laboratorios Sophia
- Start
- Mar 2011
- Primary completion
- Feb 2012
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alcaftadine in allergic conjunctivitis (AC) (5 arms), sponsored by Laboratorios Sophia. Primary endpoint: Evaluation of ocular itching at 21 days. Planned start Mar 2011; status: withdrawn.
02
Drugs
alcaftadine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT01541904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01541904.